Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Other financing activities: 2020-2024

Historic Other financing activities for SAB Biotherapeutics (SABS) over the last 5 years, with Dec 2024 value amounting to $24,931.

  • SAB Biotherapeutics' Other financing activities was N/A to $4,881 in Q3 2025 from the same period last year, while for Sep 2025 it was $29,795, marking a year-over-year change of. This contributed to the annual value of $24,931 for FY2024, which is 160.19% up from last year.
  • Per SAB Biotherapeutics' latest filing, its Other financing activities stood at $24,931 for FY2024, which was up 160.19% from $9,582 recorded in FY2023.
  • In the past 5 years, SAB Biotherapeutics' Other financing activities registered a high of $1.3 million during FY2020, and its lowest value of $6,750 during FY2021.
  • In the last 3 years, SAB Biotherapeutics' Other financing activities had a median value of $24,931 in 2024 and averaged $37,161.
  • As far as peak fluctuations go, SAB Biotherapeutics' Other financing activities crashed by 99.48% in 2021, and later surged by 1,040.31% in 2022.
  • Over the past 5 years, SAB Biotherapeutics' Other financing activities (Yearly) stood at $1.3 million in 2020, then slumped by 99.48% to $6,750 in 2021, then soared by 1,040.31% to $76,971 in 2022, then crashed by 87.55% to $9,582 in 2023, then skyrocketed by 160.19% to $24,931 in 2024.